S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NYSE:MMS

Maximus Stock Forecast, Price & News

$77.22
-3.50 (-4.34%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$77.04
$79.75
50-Day Range
$77.22
$86.94
52-Week Range
$67.65
$96.05
Volume
308,560 shs
Average Volume
309,367 shs
Market Capitalization
$4.78 billion
P/E Ratio
16.57
Dividend Yield
1.39%
Beta
0.76
30 days | 90 days | 365 days | Advanced Chart
Receive MMS News and Ratings via Email

Sign-up to receive the latest news and ratings for Maximus and its competitors with MarketBeat's FREE daily newsletter.


Maximus logo

About Maximus

MAXIMUS, Inc. engages in the operation of government and human services programs. It operates through the following segments: U.S. Services; U.S. Federal Services; and Outside the U.S. The U.S. Services segment offers a variety of business process services, and appeals and assessments for state, provincial and national government programs. The U.S. Federal Services segment includes process solutions, program management, as well as system and software development, and maintenance services for various United States federal civilian programs. The Outside the U.S segment comprises of national, state, and county human services agencies with a variety of business process services, and related consulting services for welfare-to-work, child support, higher education institutions, and other human services programs. The company was founded by David V. Mastran in 1975 and is headquartered in Reston, VA.

Headlines

MAXIMUS (MMS) Q4 Earnings Surpass Estimates, Increase Y/Y
November 19, 2021 |  finance.yahoo.com
Maximus Inc (MMS) Q4 2021 Earnings Call Transcript
November 18, 2021 |  finance.yahoo.com
Maximus (MMS) Q4 Earnings and Revenues Surpass Estimates
November 18, 2021 |  finance.yahoo.com
Earnings Preview For Maximus - Benzinga - Benzinga
November 17, 2021 |  benzinga.com
A Look Into Maximus Price Over Earnings - Benzinga
November 16, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
Data Processing & Outsourced Services
CUSIP
57793310
Employees
35,800
Year Founded
1975

Sales & Book Value

Annual Sales
$4.25 billion
Cash Flow
$6.47 per share
Book Value
$23.89 per share

Profitability

Net Income
$291.20 million
Pretax Margin
9.02%

Debt

Price-To-Earnings

Miscellaneous

Free Float
60,777,000
Market Cap
$4.78 billion
Optionable
Optionable

Company Calendar

Ex-Dividend
11/12/2021
Last Earnings
11/18/2021
Today
11/28/2021
Dividend Payable
11/30/2021
Next Earnings (Estimated)
2/03/2022
Fiscal Year End
9/30/2022

Social Links


MarketRank

Overall MarketRank

2.90 out of 5 stars

Business Services Sector

9th out of 420 stocks

Business Services, Not Elsewhere Classified Industry

8th out of 136 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 2.5Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












Maximus (NYSE:MMS) Frequently Asked Questions

Is Maximus a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Maximus in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Maximus stock.
View analyst ratings for Maximus
or view top-rated stocks.

How has Maximus' stock been impacted by COVID-19?

Maximus' stock was trading at $60.94 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MMS shares have increased by 26.7% and is now trading at $77.22.
View which stocks have been most impacted by COVID-19
.

When is Maximus' next earnings date?

Maximus is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Maximus
.

How were Maximus' earnings last quarter?

Maximus, Inc. (NYSE:MMS) issued its quarterly earnings data on Thursday, November, 18th. The health services provider reported $1.08 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.87 by $0.21. The health services provider had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.08 billion. Maximus had a trailing twelve-month return on equity of 22.53% and a net margin of 6.84%. The business's quarterly revenue was up 19.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.02 EPS.
View Maximus' earnings history
.

How often does Maximus pay dividends? What is the dividend yield for Maximus?

Maximus announced a quarterly dividend on Thursday, October 14th. Stockholders of record on Monday, November 15th will be paid a dividend of $0.28 per share on Tuesday, November 30th. This represents a $1.12 dividend on an annualized basis and a yield of 1.45%. The ex-dividend date of this dividend is Friday, November 12th.
View Maximus' dividend history
.

Is Maximus a good dividend stock?

Maximus pays an annual dividend of $1.12 per share and currently has a dividend yield of 1.39%. The dividend payout ratio of Maximus is 24.03%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Maximus will have a dividend payout ratio of 20.14% next year. This indicates that Maximus will be able to sustain or increase its dividend.
View Maximus' dividend history.

What guidance has Maximus issued on next quarter's earnings?

Maximus issued an update on its FY 2022 earnings guidance on Thursday, November, 25th. The company provided earnings per share guidance of $5.070-$5.370 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.450. The company issued revenue guidance of $4.40 billion-$4.60 billion, compared to the consensus revenue estimate of $4.12 billion.

What price target have analysts set for MMS?

2 brokerages have issued 1-year price objectives for Maximus' stock. Their forecasts range from $95.00 to $105.00. On average, they anticipate Maximus' share price to reach $100.00 in the next twelve months. This suggests a possible upside of 29.5% from the stock's current price.
View analysts' price targets for Maximus
or view top-rated stocks among Wall Street analysts.

Who are Maximus' key executives?

Maximus' management team includes the following people:
  • Bruce L. Caswell, Co-President, Chief Executive Officer & Director
  • Manish Agarwal, Co-President
  • Richard J. Nadeau, Chief Financial Officer & Treasurer
  • Michael S. Weiner, Chief Medical Officer
  • John W. Lambeth, Chief Information Officer

What is Bruce Caswell's approval rating as Maximus' CEO?

145 employees have rated Maximus CEO Bruce Caswell on Glassdoor.com. Bruce Caswell has an approval rating of 80% among Maximus' employees.

What other stocks do shareholders of Maximus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Maximus investors own include Pfizer (PFE), Lennar (LEN), AbbVie (ABBV), Cisco Systems (CSCO), Kroger (KR), Skyworks Solutions (SWKS), Advanced Micro Devices (AMD), Cerner (CERN), Intel (INTC) and JD.com (JD).

What is Maximus' stock symbol?

Maximus trades on the New York Stock Exchange (NYSE) under the ticker symbol "MMS."

Who are Maximus' major shareholders?

Maximus' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.47%), Victory Capital Management Inc. (6.87%), Alliancebernstein L.P. (5.12%), Mackenzie Financial Corp (4.23%), Mondrian Investment Partners LTD (2.44%) and Janus Henderson Group PLC (2.03%). Company insiders that own Maximus stock include Bruce Caswell, David Francis, Ilene R Baylinson, Michelle F Link, Peter Pond, Raymond B Ruddy, Richard A Montoni, Richard John Nadeau and Thomas D Romeo.
View institutional ownership trends for Maximus
.

Which major investors are selling Maximus stock?

MMS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Boston Partners, Raymond James & Associates, Renaissance Technologies LLC, Citadel Advisors LLC, Handelsbanken Fonder AB, Man Group plc, and AXA S.A.. Company insiders that have sold Maximus company stock in the last year include David Francis, Ilene R Baylinson, Michelle F Link, Peter Pond, Raymond B Ruddy, Richard A Montoni, Richard John Nadeau, and Thomas D Romeo.
View insider buying and selling activity for Maximus
or view top insider-selling stocks.

Which major investors are buying Maximus stock?

MMS stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Alliancebernstein L.P., Mackenzie Financial Corp, Robeco Schweiz AG, Goldman Sachs Group Inc., Nordea Investment Management AB, 12th Street Asset Management Company LLC, and Mondrian Investment Partners LTD.
View insider buying and selling activity for Maximus
or or view top insider-buying stocks.

How do I buy shares of Maximus?

Shares of MMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Maximus' stock price today?

One share of MMS stock can currently be purchased for approximately $77.22.

How much money does Maximus make?

Maximus has a market capitalization of $4.78 billion and generates $4.25 billion in revenue each year. The health services provider earns $291.20 million in net income (profit) each year or $4.66 on an earnings per share basis.

How many employees does Maximus have?

Maximus employs 35,800 workers across the globe.

When was Maximus founded?

Maximus was founded in 1975.

What is Maximus' official website?

The official website for Maximus is www.maximus.com.

Where are Maximus' headquarters?

Maximus is headquartered at 1891 METRO CENTER DRIVE, RESTON VA, 20190.

How can I contact Maximus?

Maximus' mailing address is 1891 METRO CENTER DRIVE, RESTON VA, 20190. The health services provider can be reached via phone at (703) 251-8500, via email at [email protected], or via fax at 703-251-8240.


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.